Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07763288
Prevalence of Glaucoma and Normative Data of Ocular Biometry in Elderly Population in BangkokSiriraj HospitalCompleted
NCT07763288Completed
—
Prevalence of Glaucoma and Normative Data of Ocular Biometry in Elderly Populati...Siriraj Hospital
NCT07762937
Neurodynamic Tensioning Plus Grip Strengthening for Hand Grip StrengthTokat Gaziosmanpasa UniversityNot Yet RecruitingNot Applicable
NCT07762937Not Yet Recruiting
Not Applicable
Neurodynamic Tensioning Plus Grip Strengthening for Hand Grip StrengthTokat Gaziosmanpasa Unive...
NCT07762924
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryFudan UniversityRecruitingPhase 2
NCT07762924Recruiting
Phase 2
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Fol...Fudan University
NCT07764224
Cold Versus Hot Snare Endoscopic Mucosal Resection for Intermediate-Size Flat Nonpedunculated Colorectal PolypsAnyuan County People's Hospital of GanzhouNot Yet RecruitingNot Applicable
NCT07764224Not Yet Recruiting
Not Applicable
Cold Versus Hot Snare Endoscopic Mucosal Resection for Intermediate-Size Flat No...Anyuan County People's Ho...
NCT07764250
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive ImpairmentShifa Tameer-e-Millat UniversityRecruitingNot Applicable
NCT07764250Recruiting
Not Applicable
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training i...Shifa Tameer-e-Millat Uni...
NCT07762716
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762716Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTr...BreakBio Corp
NCT07764120
Quality of Life of Patients After Rectal Cancer Resection .University Hospital, GrenobleNot Yet Recruiting
NCT07764120Not Yet Recruiting
—
Quality of Life of Patients After Rectal Cancer Resection .University Hospital, Gren...
NCT07763496
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUPNot Yet RecruitingPhase 2
NCT07763496Not Yet Recruiting
Phase 2
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUP
NCT07764016
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scoring in Patients With Femoropopliteal Arterial DiseaseCardionovum GmbHNot Yet RecruitingNot Applicable
NCT07764016Not Yet Recruiting
Not Applicable
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scor...Cardionovum GmbH
NCT07762989
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longus Tendon AutograftGazi UniversityNot Yet Recruiting
NCT07762989Not Yet Recruiting
—
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longu...Gazi University
NCT07764328
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.Mila Mend Inc.RecruitingNot Applicable
NCT07764328Recruiting
Not Applicable
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Bal...Mila Mend Inc.
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07762794
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairHumacyte, Inc.Not Yet RecruitingPhase 4
NCT07762794Not Yet Recruiting
Phase 4
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real Worl...Humacyte, Inc.
NCT07763405
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic StrokeThe First Affiliated Hospital of Nanchang UniversityNot Yet RecruitingPhase 4
NCT07763405Not Yet Recruiting
Phase 4
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic StrokeThe First Affiliated Hosp...
NCT07764081
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764081Recruiting
—
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, N...
NCT07763145
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy: A Randomized Control TrialHayatabad Medical ComplexNot Yet RecruitingNot Applicable
NCT07763145Not Yet Recruiting
Not Applicable
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resisti...Hayatabad Medical Complex
NCT07762768
Effect of CSIR-Developed High-Protein, Low-Glycaemic Index Rice on Glycaemic Response in Individuals With PrediabetesCSIR National Institute for Interdisciplinary Science and Technology (NIIST), ThiruvananthapuramNot Yet RecruitingNot Applicable
NCT07762768Not Yet Recruiting
Not Applicable
Effect of CSIR-Developed High-Protein, Low-Glycaemic Index Rice on Glycaemic Res...CSIR National Institute f...
NCT07762131
AI-Based Precision Transfusion Prediction Model in Critically Ill PatientsSecond Affiliated Hospital, Zhejiang University, School of MedicineNot Yet Recruiting
NCT07762131Not Yet Recruiting
—
AI-Based Precision Transfusion Prediction Model in Critically Ill PatientsSecond Affiliated Hospita...
NCT07764315
EEG-Based Decision-Support Algorithm for Hypoxic-Ischemic Encephalopathy in Term NewbornsAssistance Publique - Hôpitaux de ParisNot Yet Recruiting
NCT07764315Not Yet Recruiting
—
EEG-Based Decision-Support Algorithm for Hypoxic-Ischemic Encephalopathy in Term...Assistance Publique - Hôp...
Result Breakdown
Not yet recruiting14 (70%)
Recruiting4 (20%)
Completed1 (5%)
Active, not recruiting1 (5%)
not_applicable8 (40%)
Not Specified6 (30%)
Phase 22 (10%)
Phase 12 (10%)
Phase 42 (10%)